IRIS
STELLA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.778
EU - Europa 2.418
AS - Asia 2.040
SA - Sud America 390
AF - Africa 336
OC - Oceania 4
Totale 8.966
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.655
SG - Singapore 992
RU - Federazione Russa 871
IT - Italia 755
CN - Cina 448
BR - Brasile 342
IE - Irlanda 222
VN - Vietnam 186
CI - Costa d'Avorio 185
IN - India 126
FR - Francia 87
UA - Ucraina 87
DE - Germania 85
CA - Canada 82
GB - Regno Unito 62
SN - Senegal 60
KR - Corea 59
BD - Bangladesh 53
FI - Finlandia 44
SE - Svezia 40
NG - Nigeria 39
IQ - Iraq 29
PL - Polonia 28
MX - Messico 26
BE - Belgio 24
ES - Italia 24
AR - Argentina 22
NL - Olanda 22
TR - Turchia 22
JP - Giappone 21
ZA - Sudafrica 19
HK - Hong Kong 17
CZ - Repubblica Ceca 16
UZ - Uzbekistan 14
ID - Indonesia 12
MA - Marocco 10
CH - Svizzera 9
AT - Austria 8
IL - Israele 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 6
GR - Grecia 6
IR - Iran 6
KE - Kenya 6
PK - Pakistan 6
PY - Paraguay 6
EC - Ecuador 5
EG - Egitto 5
HU - Ungheria 5
KZ - Kazakistan 5
TN - Tunisia 5
AU - Australia 4
CO - Colombia 4
LT - Lituania 4
NO - Norvegia 4
PE - Perù 4
RO - Romania 4
TT - Trinidad e Tobago 4
BJ - Benin 3
DO - Repubblica Dominicana 3
PS - Palestinian Territory 3
RS - Serbia 3
VE - Venezuela 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CY - Cipro 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
UY - Uruguay 2
AM - Armenia 1
BO - Bolivia 1
CG - Congo 1
CL - Cile 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
GD - Grenada 1
GL - Groenlandia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
JO - Giordania 1
MN - Mongolia 1
NA - Namibia 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 8.966
Salva come PNG Salva come JPEG
Città #
Singapore 650
Santa Clara 526
Dallas 489
Moscow 430
Chandler 326
San Jose 309
Ashburn 238
Chicago 231
Dublin 221
Catania 194
Abidjan 185
Los Angeles 105
Beijing 97
Jacksonville 97
Boardman 85
Hefei 85
Kochi 79
Lauterbourg 65
Cambridge 60
New York 60
Dakar 59
Lawrence 59
Seoul 58
Council Bluffs 57
Andover 55
Civitanova Marche 54
Ho Chi Minh City 48
Palermo 45
Hanoi 42
Milan 36
Grafing 35
Buffalo 34
Nanjing 34
São Paulo 32
Des Moines 30
Toronto 29
Wilmington 29
Montreal 28
The Dalles 27
Dong Ket 26
Columbus 25
Orem 25
Brussels 24
Rome 22
Turku 22
Warsaw 22
Tokyo 21
Bari 20
Abuja 19
Munich 19
San Giovanni la Punta 19
Chennai 18
Johannesburg 17
Lagos 16
Lappeenranta 15
London 15
Hong Kong 14
Brno 13
Messina 13
Ottawa 13
San Mateo 13
Seattle 13
Stockholm 13
Rio de Janeiro 12
Santa Venerina 12
Belo Horizonte 11
Brooklyn 11
Haiphong 11
Jiaxing 11
Manchester 11
Nanchang 11
Amsterdam 10
Baghdad 10
Boston 10
Falls Church 10
Tashkent 10
Aci Catena 9
Bremen 9
Da Nang 9
Phoenix 9
Saint Petersburg 9
Atlanta 8
Curitiba 8
Houston 8
San Francisco 8
Brasília 7
Casablanca 7
Denver 7
Florence 7
Frankfurt am Main 7
Hanover 7
Hebei 7
Helsinki 7
Jakarta 7
Poplar 7
Pune 7
Querétaro 7
Redmond 7
Elk Grove Village 6
Mexico City 6
Totale 6.080
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 227
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 207
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 192
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 183
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 181
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 175
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 169
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 169
Biomarkers and prognostic factors for malignant pleural mesothelioma 167
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 164
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 161
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 160
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 160
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 158
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 158
A case of high-risk AML in a patient with advanced systemic mastocytosis 156
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 156
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 154
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 154
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 149
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 147
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 145
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 145
New insights in thyroid cancer and p53 family proteins 141
Rufloxacin induced photosensitization in bio-models of increasing complexity 137
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 137
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 135
Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay. 132
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 130
Opportunities and challenges of liquid biopsy in thyroid cancer 130
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 130
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 128
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 127
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 127
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 126
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 125
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis 121
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 120
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 120
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 119
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 119
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 116
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 116
Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato 113
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 113
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 113
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 112
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 112
Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51 111
Uncommon long-term survival in a patient with chronic myeloid leukemia 110
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 110
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 108
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 98
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 96
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 95
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 94
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 93
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 93
The Role of New Technologies in Myeloproliferative Neoplasms 92
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 91
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 89
REThinking the role of the RET oncogene in breast cancer 88
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 88
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 86
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 85
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 84
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment 73
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 73
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 72
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer 71
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 70
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 66
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes 64
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model 6
The Coiled Coil and C2 Domains Modulate BCR Localization and BCR-ABL1 Compartmentalization, Transforming Activity and TKI Responsiveness 4
Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs 3
Totale 9.149
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.287
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.287
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202135 0 0 0 0 0 0 0 0 0 0 0 35
2021/2022435 20 67 11 7 78 8 64 15 25 11 30 99
2022/20231.036 68 82 56 119 58 148 13 201 209 14 46 22
2023/2024553 44 83 26 24 19 132 8 33 7 23 112 42
2024/20252.107 30 330 79 152 412 291 166 64 75 143 255 110
2025/20264.380 253 240 584 288 657 1.041 442 89 227 288 186 85
Totale 9.149